More News

2024 ARVO Awards Highlight New Focus on Inflammation
2024 ARVO Awards Highlight New Focus on Inflammation

The Weisenfeld and Cogan awards and lectures at the 2024 ARVO meeting put a spotlight on inflammation. Martine Jager, MD, PhD (Netherlands), received the Weisenfeld Award in recognition of her pion...

Clinical Trial Updates for Ophthalmic Candidates, May 2024
Clinical Trial Updates for Ophthalmic Candidates, May 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Sight Sciences Announces $34 Million Jury Verdict in Patent Infringement Case
Sight Sciences Announces $34 Million Jury Verdict in Patent Infringement Case

Sight Sciences, of Menlo Park, California, reported April 29 that it had received a $34 million jury trial verdict in its patent infringement case against Ivantis and acquirer Alcon. The suit, file...

New Topcon Healthcare CEO, Latest Partnerships Stress Focus on ‘Oculomics’
New Topcon Healthcare CEO, Latest Partnerships Stress Focus on ‘Oculomics’

Topcon Healthcare announced April 26 that it had appointed Ali Tafreshi as CEO and president. The company said Tafreshi will lead the company’s focus on “oculomics”—diagnosing not just eye disease ...

First-in-Human Robotic Bimanual Vitrectomy Performed in Belgium
First-in-Human Robotic Bimanual Vitrectomy Performed in Belgium

The first-in-human robotic bimanual vitrectomy was performed this year at Belgium’s Ghent University Hospital. The surgeon, Fanny Nerinckx, MD, first announced the surgery on LinkedIn in March. Det...

Weekly Surgeon and Industry Poll, May 2024
Weekly Surgeon and Industry Poll, May 2024

May 2024 Ophthalmic News Briefs
May 2024 Ophthalmic News Briefs

Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...

US FDA Grants De Novo Marketing Authorization to Notal Vision’s Scanly AI-Powered Home OCT
US FDA Grants De Novo Marketing Authorization to Notal Vision’s Scanly AI-Powered Home OCT

Notal Vision announced May 16 that the US FDA had granted de novo marketing authorization for its patient-operated Scanly home optical coherence tomography (OCT) device. The Scanly uses artificial ...

Q1-2024 Ophthalmic Revenue Roundup for Alcon, Carl Zeiss Meditec, and Harrow
Q1-2024 Ophthalmic Revenue Roundup for Alcon, Carl Zeiss Meditec, and Harrow

Alcon reported May 13 that its Q1-2024 net sales were $2.4 billion, a 5 percent increase (+7 percent cc) over $2.3 billion in Q1-2023. Surgical net sales totaled $1.34 billion, consisting of $433 m...

First-in-Human Robotic Bimanual Vitrectomy Performed in Belgium
First-in-Human Robotic Bimanual Vitrectomy Performed in Belgium

Healio reported May 14 that the first-in-human bimanual vitrectomy performed with a robot had taken place at Belgium’s Ghent University Hospital. The case was presented at the Retina World Congress...

Xbrane, Stada Partner with Valorum to Commercialize Ranibizumab Biosimilar Candidate in US
Xbrane, Stada Partner with Valorum to Commercialize Ranibizumab Biosimilar Candidate in US

Partners Xbrane Biopharma, of Sweden, and Germany’s Stada announced May 10 that they had entered into an exclusive licensing agreement with biosimilar company Valorum Biologics to market their rani...

First Beyeonics One Ophthalmic Exoscope Installed at ASC in Florida
First Beyeonics One Ophthalmic Exoscope Installed at ASC in Florida

Israel’s Beyeonics Vision reported May 10 the first commercial installation of a Beyeonics One digital ophthalmic exoscope at Largo Ambulatory Surgery Center & Eye Institute in Largo, Florida. The ...

Formosa Licenses Clobetasol Propionate Drops to Tabuk Pharmaceuticals for MENA Region
Formosa Licenses Clobetasol Propionate Drops to Tabuk Pharmaceuticals for MENA Region

Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...

Outlook Submits UK Marketing Application for Ophthalmic Bevacizumab in Wet AMD
Outlook Submits UK Marketing Application for Ophthalmic Bevacizumab in Wet AMD

Outlook Therapeutics announced May 13 that it had submitted a marketing authorization application to the UK’s Medicines and Healthcare Products Regulatory Agency for ONS-5010 (bevacizumab gamma) fo...

Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335 Million
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335 Million

Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...

Q1-2024 Ophthalmic Revenue Roundup for Apellis, STAAR, RxSight, Tarsus, Sight Sciences, and Three Others
Q1-2024 Ophthalmic Revenue Roundup for Apellis, STAAR, RxSight, Tarsus, Sight Sciences, and Three Others

Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 that its Q1-2024 US net product revenue for Syfovre was $137.5 million, compared with $18.4 million in Q1-2023. Syfovre gained US ...

Bausch + Lomb Launches Zenlens Echo Scleral Lenses in the US
Bausch + Lomb Launches Zenlens Echo Scleral Lenses in the US

Bausch + Lomb announced May 7 that it had launched the Zenlens Echo, a non-prosthetic, custom scleral contact lens, in the US. The company said the Echo is designed to fit a wide variety of corneal...

First-in-Human Study for Injectsense Implantable IOP Monitor Approved by Chilean Clinic
First-in-Human Study for Injectsense Implantable IOP Monitor Approved by Chilean Clinic

Injectsense announced May 6 that the ethics committee at the Centro de la Vision Clinic in Santiago, Chile, has approved a 20-patient study of the company’s ultra-miniature wireless sensor, designe...

EyePoint’s Duravyu Misses Primary Endpoint in Phase II Trial in NPDR
EyePoint’s Duravyu Misses Primary Endpoint in Phase II Trial in NPDR

EyePoint Pharmaceuticals reported May 6 that Duravyu (vorolanib intravitreal insert) missed its primary endpoint of improvement in Diabetic Retinopathy Severity Scale score in patients with non-pro...

ArcScan Computer-Controlled Ophthalmic Ultrasound Gains Approval in China
ArcScan Computer-Controlled Ophthalmic Ultrasound Gains Approval in China

ArcScan announced May 1 that its Insight 100 computer-controlled ophthalmic ultrasound imaging device received National Medical Products Administration (NMPA) approval in China. ArcScan, of Denver,...

Lumibird Launches C.Diag Diagnostic Platform for Dry Eye
Lumibird Launches C.Diag Diagnostic Platform for Dry Eye

France’s Lumibird Medical announced May 3 that it had launched C.Diag, a dry eye diagnostic imaging platform incorporating artificial intelligence, after gaining the European Union’s CE marking for...

Remidio Places its Thousandth Smartphone-Based Fundus Camera in US
Remidio Places its Thousandth Smartphone-Based Fundus Camera in US

Remidio Inc., the US arm of India-based Remidio, announced May 7 that it had placed its thousandth FOP-NM hand-held fundus camera in the US. Remidio’s FOP-NM is the world’s first smartphone-based n...

US FDA Approves Aeye’s Autonomous AI DR Screening with Hand-held Fundus Camera
US FDA Approves Aeye’s Autonomous AI DR Screening with Hand-held Fundus Camera

Aeye Health announced April 30 that the US FDA had approved the company’s autonomous artificial intelligence-aided screening technology for diabetic retinopathy (DR) using a hand-held retinal camer...

Q1-2024 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, and Lumibird
Q1-2024 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, and Lumibird

Bausch + Lomb reported May 1 that its Q1-2024 revenue was $1.1 billion, an 18 percent increase (+20 percent cc) over $931 million in Q1-2023. Vision Care segment revenue in Q1-2024 was $635 million...

Sight Sciences Announces $34 Million Jury Verdict in Patent Infringement Case
Sight Sciences Announces $34 Million Jury Verdict in Patent Infringement Case

Sight Sciences, of Menlo Park, California, reported April 29 that ithad received a $34 million jury trial verdict in its patent infringement case against Ivantis and acquirer Alcon. The suit, filed...

OcuTerra to Wind Down Operations After Disappointing Phase II Results in DR
OcuTerra to Wind Down Operations After Disappointing Phase II Results in DR

OcuTerra Therapeutics, of Boston, Massachusetts, announced May 1 on LinkedIn that it would wind down operations. The company had been developing nesvategrast (OTT166 5%), an eye drop candidate for ...

California-Based Science Corporation Acquires Pixium Vision’s Prima Implant
California-Based Science Corporation Acquires Pixium Vision’s Prima Implant

Science Corporation, of Alameda, California, reported April 25 that it had acquiredthe IP and related assets for the Prima retinal implant, developed by Pixium Vision SA, of France. Terms of the de...

US FDA Approves Preservative-Free Lumify Drops from Bausch + Lomb
US FDA Approves Preservative-Free Lumify Drops from Bausch + Lomb

Bausch + Lomb announced April 26 that the US FDA had approved a preservative-free formulation of Lumify redness reliever eye drops. Lumify is an over-the-counter formulation of low-dose brimonidine...

Aldeyra Plans US Pivotal Trial for Methotrexate Injection in RP
Aldeyra Plans US Pivotal Trial for Methotrexate Injection in RP

Aldeyra Therapeutics said April 25 that it planned to initiate a pivotal Phase II/III trial for ADX-2191 (methotrexate injection) in patients with retinitis pigmentosa due to rhodopsin misfolding m...

US FDA Accepts IND for Eluminex’ Tri-specific Antibody Candidate for DME
US FDA Accepts IND for Eluminex’ Tri-specific Antibody Candidate for DME

China-headquartered Eluminex Biosciences announced April 30 that the US FDA had accepted its investigational new drug (IND) application for EB-105, a tri-specific fusion antibody candidate for diab...

Topcon Healthcare Appoints Ali Tafreshi as President, CEO to Lead Focus on Oculomics
Topcon Healthcare Appoints Ali Tafreshi as President, CEO to Lead Focus on Oculomics

Topcon Healthcare announced April 26 that it had appointed Ali Tafreshi as CEO and president. The company said Tafreshi will lead the company’s focus on “oculomics”—diagnosing not just eye health b...

Euretina President Ramin Tadayoni, MD, PhD, Dies at 54
Euretina President Ramin Tadayoni, MD, PhD, Dies at 54

The European Society of Retina Specialists, or Euretina, reported April 20 that its president, retina specialist Ramin Tadayoni, MD, PhD, had died. He was 54. Tadayoni was attending the Brazilian R...

Q1-2024 Ophthalmic Revenue Roundup for Roche, Novartis, and Nicox
Q1-2024 Ophthalmic Revenue Roundup for Roche, Novartis, and Nicox

Swiss company Roche reported April 24 that Vabysmo sales in Q1-2024 were CHF 847 million ($926.5 million, calculated April 24, 2024), up from CHF 432 million (US $487 million) in Q1-2023. Vabysmo r...

US FDA Rejects Xbrane’s Ranibizumab Biosimilar, Citing Analysis and Manufacturing Issues
US FDA Rejects Xbrane’s Ranibizumab Biosimilar, Citing Analysis and Manufacturing Issues

Sweden’s Xbrane Biopharma announced April 21 that the US FDA had issued a complete response letter rejecting Xbrane’s ranibizumab biosimilar, branded in Europe as Ximluci. The company said regulato...

New Products Set Upbeat Tone for ASCRS Meeting; Attendance Remains a Concern
New Products Set Upbeat Tone for ASCRS Meeting; Attendance Remains a Concern

New product launches created high surgeon interest at the 2024 meeting of the American Society of Cataract and Refractive Surgery (ASCRS), but the overall mood of the conference was tempered somewh...

Researchers in Georgia Establish Database of Proteins in Aqueous Humor to Advance Vision Research
Researchers in Georgia Establish Database of Proteins in Aqueous Humor to Advance Vision Research

The National Eye Institute (NEI) announced April 8 that researchers from the Medical College of Georgia at Augusta University had established a database of the proteins found in the eye’s aqueous h...

Second Shake-up May be Underway in the Glaucoma Pharmaceuticals Market
Second Shake-up May be Underway in the Glaucoma Pharmaceuticals Market

Allergan and Novartis replaced Merck and Pfizer at the top of the glaucoma pharmaceuticals market a decade ago. Now it could be their turn to pass the baton. Allergan, acquired by AbbVie in 2020 an...

Retinal Pharmaceutical Transactions Drive Ophthalmic Deals in First Quarter of 2024
Retinal Pharmaceutical Transactions Drive Ophthalmic Deals in First Quarter of 2024

Ophthalmic deals in Q1-2024 reached over $2.1 billion and involved 20 transactions. This compares with $2.0 billion from 17 transactions in Q1-2023 and $570 million from 12 transactions in Q4-2023....

Refractive Atlas Uncovers Pockets of High Opportunity in Des Moines, Syracuse
Refractive Atlas Uncovers Pockets of High Opportunity in Des Moines, Syracuse

Refractive procedures in general are driven by the country’s millennial and older Generation Z populations, but the surgery rate is driven by a subset of comparatively educated, affluent, and healt...

Viatris, Ocuphire Announce US Launch of Ryzumvi to Reverse Pupil Dilation
Viatris, Ocuphire Announce US Launch of Ryzumvi to Reverse Pupil Dilation

Viatris and Ocuphire Pharma announced April 1 the US launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the reversal of pharmacologically induced mydriasis. The US FDA approved Ryzumvi ...

Japanese IOL Maker Hoya Halts Production After Cyberattack
Japanese IOL Maker Hoya Halts Production After Cyberattack

Japanese intraocular lens maker Hoya reported on April 4 that production of several of its products had stopped after a computer system failure, “most likely caused by unauthorized access” to its s...

iDose, Eylea HD, Izervay Get J-Codes for Billing Payers in the US
iDose, Eylea HD, Izervay Get J-Codes for Billing Payers in the US

The Centers for Medicare and Medicaid Services (CMS) has issued J-codes for Glaukos’ iDose, Regeneron’s Eylea HD, and Astellas Pharma’s Izervay. The code for iDose takes effect July 1, 2024, while ...

Lenz Reports Positive Topline Phase III Data  in Presbyopia, Plans NDA Submission in Mid-2024
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024

Lenz Therapeutics reported April 3 positive topline results from its Phase III CLARITY trials of LNZ100 and LNZ101 for presbyopia. LNZ100 and LNZ101 are preservative free, single-use, once-daily ey...

Select US FDA Approvals and Clearances in March 2024
Select US FDA Approvals and Clearances in March 2024

The US FDA granted three clearances through the ophthalmic device division using the 510(k) pathway in March 2024, according to the agency’s database. Cylite received clearance for its HP-OCT. The ...

Ophthalmic Bevacizumab Candidate from Outlook Gains Positive CHMP Opinion
Ophthalmic Bevacizumab Candidate from Outlook Gains Positive CHMP Opinion

Outlook Therapeutics announced March 22 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion recommending approval of ONS-5010 (L...

Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements
Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements

Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...

Warburg Pincus Buys Controlling Stake in India’s Appasamy
Warburg Pincus Buys Controlling Stake in India’s Appasamy

US-based private equity firm Warburg Pincus and Appasamy Associates announced April 10 that Warburg had bought a controlling stake in the Indian ophthalmic company. Financial details were not discl...

ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front

ABVC BioPharma announced March 26 that it had agreed to license its ophthalmology pipeline, including the vitreous substitute candidate Vitargus, to ForSeeCon Eye. ABVC, of Fremont, California, say...

Study Attempts to Clarify Best Fit for Vyzulta
Study Attempts to Clarify Best Fit for Vyzulta

Constance Okeke, MD, is helping to clear the confusion that can come from having multiple choices. “There are so many medicines coming into glaucoma that it can be difficult for a clinician to know...

US FDA Backs Call to Eliminate Interchangeability Designation for Biosimilars
US FDA Backs Call to Eliminate Interchangeability Designation for Biosimilars

A US FDA official has expressed support for measures before Congress to remove the interchangeability designation for biosimilars, claiming that the two-tier system is only causing confusion. It ca...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more